Patents Assigned to Pharmaceutical Solutions, Inc.
-
Publication number: 20230277465Abstract: An oral dosage form of an antidiabetic pharmaceutical composition comprises a metformin-containing core portion, an outer portion that comprises a non-biguanide antidiabetic agent such as sitagliptin, and a controlled membrane film sandwiched therebetween. The controlled membrane film is provided with at least one passageway allowing core-residing metformin to release out when the oral dosage form is in an aqueous environment, such as in the gastrointestinal (GI) tract of a subject. The oral dosage form has a dissolution profile such that upon dissolving in a medium with a pH of approximately 6.8 at approximately 37° C., less than 15% of the metformin is released at approximately 1 hours, and approximately 45-99% of the metformin is released at approximately 12 hours. The oral dosage form can provide a maximum plasma concentration of the metformin from approximately 7.5 to 15 hours after single-dose oral administration.Type: ApplicationFiled: May 10, 2023Publication date: September 7, 2023Applicant: ELITE PHARMACEUTICAL SOLUTION INC.Inventors: Wu TIAN, Yan WANG, Henry TIAN
-
Patent number: 11723873Abstract: An oral dosage form of ticagrelor includes a core and a semi-permeable membrane coating the core. The core comprises a first drug layer and a push layer. The first drug layer contains ticagrelor that is sufficient to deliver an effective amount of the drug over an intended delivery time. The push layer comprises a swelling agent and an osmogen agent. The semi-permeable membrane has at least one passageway formed therethrough, positionally configured to face the first drug layer, but not to face the push layer, of the core, and functionally configured to allow the ticagrelor to realize an extended release out of the core upon contacting an aqueous environment. The dosage form optionally further includes a second ticagrelor-containing drug layer coating the semi-permeable membrane, thereby providing a starting effective dose upon administration. The dosage form can realize once-a-day administration of ticagrelor of patients in need thereof.Type: GrantFiled: June 23, 2021Date of Patent: August 15, 2023Assignee: Elite Pharmaceutical Solution Inc.Inventors: Wu Tian, Yan Wang, Henry Tian
-
Patent number: 11684596Abstract: An oral dosage form of an antidiabetic pharmaceutical composition comprises a core portion, an outer portion, and a controlled membrane film sandwiched therebetween. The core and outer portions respectively comprise a first antidiabetic agent and a second antidiabetic agent, such as metformin HCl and sitagliptin phosphate, each at a therapeutically effective amount. The controlled membrane film encapsulates the core portion and is provided with at least one passageway for allowing the first antidiabetic agent to release out when the oral dosage form is in an aqueous environment, such as in the gastrointestinal (GI) tract of a subject. The oral dosage form is configured, upon a single-dose oral administration, to provide a maximum plasma concentration of the first antidiabetic agent in the subject from approximately 7.5 to 15 hours after administration. A method for manufacturing the oral dosage form of the antidiabetic pharmaceutical composition is also provided.Type: GrantFiled: September 22, 2020Date of Patent: June 27, 2023Assignee: Elite Pharmaceuticals Solution Inc.Inventors: Wu Tian, Yan Wang
-
Publication number: 20220409545Abstract: An oral dosage form of ticagrelor includes a core and a semi-permeable membrane coating the core. The core comprises a first drug layer and a push layer. The first drug layer contains ticagrelor that is sufficient to deliver an effective amount of the drug over an intended delivery time. The push layer comprises a swelling agent and an osmogen agent. The semi-permeable membrane has at least one passageway formed therethrough, positionally configured to face the first drug layer, but not to face the push layer, of the core, and functionally configured to allow the ticagrelor to realize an extended release out of the core upon contacting an aqueous environment. The dosage form optionally further includes a second ticagrelor-containing drug layer coating the semi-permeable membrane, thereby providing a starting effective dose upon administration. The dosage form can realize once-a-day administration of ticagrelor of patients in need thereof.Type: ApplicationFiled: June 23, 2021Publication date: December 29, 2022Applicant: Elite Pharmaceutical Solution Inc.Inventors: Wu TIAN, Yan WANG, Henry TIAN
-
Publication number: 20220087958Abstract: An oral dosage form of an antidiabetic pharmaceutical composition comprises a core portion, an outer portion, and a controlled membrane film sandwiched therebetween. The core and outer portions respectively comprise a first antidiabetic agent and a second antidiabetic agent, such as metformin HCl and sitagliptin phosphate, each at a therapeutically effective amount. The controlled membrane film encapsulates the core portion and is provided with at least one passageway for allowing the first antidiabetic agent to release out when the oral dosage form is in an aqueous environment, such as in the gastrointestinal (GI) tract of a subject. The oral dosage form is configured, upon a single-dose oral administration, to provide a maximum plasma concentration of the first antidiabetic agent in the subject from approximately 7.5 to 15 hours after administration. A method for manufacturing the oral dosage form of the antidiabetic pharmaceutical composition is also provided.Type: ApplicationFiled: September 22, 2020Publication date: March 24, 2022Applicant: Elite Pharmaceutical Solution Inc.Inventors: Wu TIAN, Yan WANG
-
Publication number: 20210161994Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active octreotide at a constant rate for an extended period of time and methods of manufactures thereof. The device is very bio-compatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of octreotide to tissues or organs.Type: ApplicationFiled: February 10, 2021Publication date: June 3, 2021Applicant: Endo Pharmaceuticals Solutions Inc.Inventors: Petr Kuzma, Harry Quandt
-
Patent number: 10891260Abstract: Methods and systems are disclosed for analyzing equipment data, determining an occurrence of an event, and transmitting a message based on the event.Type: GrantFiled: May 31, 2019Date of Patent: January 12, 2021Assignee: RMC PHARMACEUTICAL SOLUTIONS, INC.Inventors: Scott Rudge, Korben Knudson
-
Publication number: 20200289420Abstract: An oral dosage form of a pharmaceutical composition for managing diabetes in a subject is provided, which comprises a core, a controlled membrane film, and an outer film. The core comprises a first antidiabetic agent. The controlled membrane film coats the core tablet and can realize a controlled release of the first antidiabetic agent from the core into a portion of a digestive tract of the subject corresponding to a stomach and an upper gastrointestinal tract after the pharmaceutical composition is orally administered to the subject. The controlled membrane film comprises at least one controlling polymer, each selected from an Eudragit polymer, an Aquacoat polymer, or an Ethocel polymer. The outer film comprises a second antidiabetic agent, and coats the controlled membrane film. A method for manufacturing an oral dosage form of a pharmaceutical composition is also provided.Type: ApplicationFiled: March 17, 2019Publication date: September 17, 2020Applicant: Elite Pharmaceutical Solution Inc.Inventors: Wu TIAN, Yan WANG, Jimmy SOOROOJBALLIE
-
Publication number: 20200046806Abstract: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.Type: ApplicationFiled: August 22, 2019Publication date: February 13, 2020Applicant: Endo Pharmaceuticals Solutions Inc.Inventors: Petr Kuzma, Stefanie Decker
-
Publication number: 20190388500Abstract: Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent.Type: ApplicationFiled: September 9, 2019Publication date: December 26, 2019Applicant: Endo Pharmaceuticals Solutions Inc.Inventors: Petr Kuzma, Stephanie Decker
-
Publication number: 20190365847Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active octreotide at a constant rate for an extended period of time and methods of manufactures thereof. The device is very bio-compatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of octreotide to tissues car organs.Type: ApplicationFiled: June 28, 2019Publication date: December 5, 2019Applicant: Endo Pharmaceuticals Solutions Inc.Inventors: Petr Kuzma, Harry Quandt
-
Patent number: 10353868Abstract: Methods and systems are disclosed for analyzing equipment data, determining an occurrence of an event, and transmitting a message based on the event.Type: GrantFiled: May 30, 2018Date of Patent: July 16, 2019Assignee: RMC PHARMACEUTICAL SOLUTIONS, INC.Inventors: Scott Rudge, Korben Knudson
-
Publication number: 20170100461Abstract: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.Type: ApplicationFiled: August 24, 2016Publication date: April 13, 2017Applicant: ENDO PHARMACEUTICALS SOLUTIONS INC.Inventors: Petr Kuzma, Stefanie Decker
-
Publication number: 20170049850Abstract: Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent.Type: ApplicationFiled: August 24, 2016Publication date: February 23, 2017Applicant: ENDO PHARMACEUTICALS SOLUTIONS INC.Inventors: PETR KUZMA, STEFANIE DECKER
-
Publication number: 20160193280Abstract: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).Type: ApplicationFiled: November 9, 2015Publication date: July 7, 2016Applicant: Endo Pharmaceuticals Solutions Inc.Inventor: Petr KUZMA
-
Publication number: 20150283201Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active octreotide at a constant rate for an extended period of time and methods of manufactures thereof. The device is very bio-compatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of octreotide to tissues or organs.Type: ApplicationFiled: November 6, 2014Publication date: October 8, 2015Applicant: Endo Pharmaceuticals Solutions Inc.Inventors: Petr Kuzma, Harry Quandt
-
Patent number: 9120249Abstract: Medical implant devices are prepared from a polymeric material and a release agent, where the device is a molded, reservoir implant, and the release agent has a molecular weight (MW) of at least 1000. The release agent may be a non-ionic surfactant such as Brij 35, polyoxyetheylene(20)sorbitan trioleate, Tween 20, Tween 80, vitamin E TPGS, and a mixture of any two or more thereof. Hydrated implants may have a surface area of about 500 mm2 or greater.Type: GrantFiled: April 25, 2008Date of Patent: September 1, 2015Assignee: ENDO PHARMACEUTICALS SOLUTIONS INC.Inventors: Petr Kuzma, Stephanie Decker, Harry Quandt
-
Publication number: 20150190413Abstract: Compositions and methods for the treatment of bladder cancer include intravesical dosage forms of a neoplastic agent and a permeation enhancer. The neoplastic agent may be valrubicin. Pharmaceutical compositions include intravesical dosage forms of a neoplastic agent complexed liposomes. Tight junction openers may be used for the effective delivery of the neoplastic agent.Type: ApplicationFiled: March 20, 2015Publication date: July 9, 2015Applicant: Endo Pharmaceuticals Solutions Inc.Inventors: John CHABER, Petr KUZMA, Agis KYDONIEUS
-
Patent number: 9072786Abstract: Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof.Type: GrantFiled: May 20, 2013Date of Patent: July 7, 2015Assignee: ENDO PHARMACEUTICALS SOLUTIONS INC.Inventors: Petr Kuzma, Stefanie Decker, Harry Quandt
-
Publication number: 20140349936Abstract: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).Type: ApplicationFiled: August 11, 2014Publication date: November 27, 2014Applicant: Endo Pharmaceuticals Solutions Inc.Inventor: Petr KUZMA